<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076370</url>
  </required_header>
  <id_info>
    <org_study_id>2000029286</org_study_id>
    <nct_id>NCT05076370</nct_id>
  </id_info>
  <brief_title>Safety of Cannabidiol Given to Subject With Methadone or Buprenorphine</brief_title>
  <official_title>Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an&#xD;
      adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a&#xD;
      randomized, placebo-controlled, crossover human laboratory study investigating the&#xD;
      dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in&#xD;
      outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or&#xD;
      buprenorphine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An initial safety pilot phase will recruit six participants: three receiving treatment with&#xD;
      methadone and three receiving treatment with buprenorphine. If the results of the pilot study&#xD;
      support the safety of CBD administration in this clinical sample, the general study will&#xD;
      recruit 48 participants with comorbid OUD and chronic pain, for a total of 24 completers - 12&#xD;
      subjects (6 men and 6 women) receiving methadone and 12 subjects (6 men and 6 women)&#xD;
      receiving buprenorphine. Both sub-studies will enroll participants who do not currently&#xD;
      require an inpatient hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Initial safety pilot phase of 6 participants,(3 methadone and 3 on Buprenorphine) The general study is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or buprenorphine.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Threshold</measure>
    <time_frame>4 measurements per test day, 3 total test days</time_frame>
    <description>The Cold Pressor (CPT measures Pain threshold (in seconds). For this test, a cooler filled with cold water (32.9-34.7degrees F/0.5-1.5 degrees C) are used. Participants are instructed to immerse their hand into the water and report the first time they experience pain (pain threshold). Lower scores indicate lower pain threshold. Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Tolerance</measure>
    <time_frame>4 measurements per test day, 3 total test days</time_frame>
    <description>The Cold Pressor Test (CPT) measures pain threshold and pain tolerance (in seconds). For this test, a water cooler is filled with cold water (32.9-34.7ºF/0.5-1.5ºC) are used. To begin the CPT, Participants are then instructed to immerse their hand into the cold water bath and report when the pain becomes unbearable (pain tolerance). Lower scores indicate lower pain tolerance. Minimum score is 0 seconds, and a maximum cut-off score of 300 seconds is used to prevent tissue damage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Threshold</measure>
    <time_frame>4 measurements per test day, 3 total test days</time_frame>
    <description>The QST is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Tolerance</measure>
    <time_frame>4 Measurements per test day, 3 total days.</time_frame>
    <description>The QST is a reliable, dynamic, and computerized method of quantifying distinct mechanisms of the pain experience</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Addiction</condition>
  <arm_group>
    <arm_group_label>CBD 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD 800mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD 1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 1200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD Day 1</intervention_name>
    <description>CBD 400mg</description>
    <arm_group_label>CBD 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD Day 2</intervention_name>
    <description>CBD 800mg</description>
    <arm_group_label>CBD 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD Day 3</intervention_name>
    <description>CBD 1200mg</description>
    <arm_group_label>CBD 1200mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, Veterans and non-Veterans, aged between 18 and 70 years old.&#xD;
&#xD;
          -  Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance&#xD;
             treatment.&#xD;
&#xD;
          -  Having chronic pain, uniformly operationalized as grade II (high-intensity) non-&#xD;
             cancer pain for ≥ 6 months 49.&#xD;
&#xD;
          -  Capable of providing informed consent in English.&#xD;
&#xD;
          -  Compliant in opioid maintenance treatment and on a stable dose for four weeks or&#xD;
             longer.&#xD;
&#xD;
          -  Not meeting DSM-5 criteria for substance use disorders other than OUD or tobacco use&#xD;
             disorder within the last 12 months.&#xD;
&#xD;
          -  No current medical problems deemed contraindicated for participation by principal&#xD;
             investigator.&#xD;
&#xD;
          -  For women, not pregnant as determined by pregnancy screening; not breast-feeding;&#xD;
             using acceptable birth control methods. Acceptable contraception for females includes&#xD;
             oral contraceptives, contraceptive depot injections, contraceptive subdermal implants,&#xD;
             intrauterine devices, or surgical contraception methods. Acceptable contraception for&#xD;
             males includes condoms or surgical contraception methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other current major psychiatric disorders deemed clinically unstable by the principal&#xD;
             investigator, such as severe depression and/or active suicidal ideation.&#xD;
&#xD;
          -  Having experienced major psychosocial stressors recently (≤ 6 weeks before&#xD;
             enrollment), at the discretion of the principal investigator.&#xD;
&#xD;
          -  Methadone dose under 60mg or over 100mg&#xD;
&#xD;
          -  Buprenorphine over 24mg.&#xD;
&#xD;
          -  Having received inpatient psychiatric treatment recently (≤ 60 days before&#xD;
             enrollment).&#xD;
&#xD;
          -  Candidates receiving products containing either THC or CBD will be excluded.&#xD;
&#xD;
          -  Current use regular use other prescription opioids, gabapentinoids (pregabalin,&#xD;
             gabapentin), antidepressants (SSRIs, SNRIs, TCAs), benzodiazepines, platelet&#xD;
             inhibitors (e.g., clopidogrel, apixaban, ticagrelor), or NSAIDs.&#xD;
&#xD;
          -  Current weight of less of 60 kg.&#xD;
&#xD;
          -  Allergy to sesame seed oil, which is an ingredient of the CBD formulation used.&#xD;
&#xD;
          -  Serious medical or neurological illness or treatment for a medical disorder that could&#xD;
             interfere with study participation as determined by principal investigator.&#xD;
&#xD;
          -  Participants who have elevation of liver enzymes (ALT and/or AST) 2x above the normal&#xD;
             limit or higher.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joao De Aquino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joao De Aquino, M.D.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>2916</phone_ext>
    <email>Joao.deaquino@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>4809</phone_ext>
    <email>mehmet.sofuoglu@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Veteran Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Sullivan</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>3350</phone_ext>
      <email>brendan.sullivan@va.gov</email>
    </contact>
    <investigator>
      <last_name>Mehmet Sofuoglu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Joao De Aquino</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

